Review
Version 1
Preserved in Portico This version is not peer-reviewed
New Therapeutic Targets in Vitiligo
Version 1
: Received: 5 July 2024 / Approved: 9 July 2024 / Online: 9 July 2024 (07:55:45 CEST)
How to cite: Kądziela, M.; Kutwin, M.; Karp, P.; Woźniacka, A. New Therapeutic Targets in Vitiligo. Preprints 2024, 2024070700. https://doi.org/10.20944/preprints202407.0700.v1 Kądziela, M.; Kutwin, M.; Karp, P.; Woźniacka, A. New Therapeutic Targets in Vitiligo. Preprints 2024, 2024070700. https://doi.org/10.20944/preprints202407.0700.v1
Abstract
Vitiligo is a chronic autoimmune disease characterized by progressive depigmentation of the skin caused by the selective destruction of melanocytes. Although its etiopathogenesis remains unclear, multiple factors are believed to be involved, including genetic and metabolic factors linked to cellular oxidative stress, melanocyte adhesion defects, innate and adaptive immunity. The aim of this review is to provide an overview of the current state of knowledge regarding the role of different cellular mechanisms, including cytokines and chemokines interactions in the pathogenesis of vitiligo. Although there is no definitive cure for vitiligo, excessive progress has been made and several treatments have shown favourable results. A thorough understanding of the basis of the disease, uncover promising drug targets for future research, providing clinical researchers with valuable insights for developing improved treatment options.
Keywords
treatment; biologics; biological drugs; vitiligo; Janus kinase inhibitors (JAKs); cytokines
Subject
Medicine and Pharmacology, Dermatology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
